Julio Castro

A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment

Melanie Mediavilla-Varela, Julio Castro, Alberto Chiappori et al. · Neoplasia · 2017 · 89 citations · Full text

Medicine, Immunology, Oncology +17

Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

Alberto Chiappori, Ben Creelan, Tawee Tanvetyanon et al. · Clinical Cancer Research · 2022 · 69 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)

Suresh S. Ramalingam, Jeffrey Crawford, Alex Y. Chang et al. · Annals of Oncology · 2013 · 56 citations · Full text

Medicine, Oncology, Pharmacology +9

Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC.

Alberto Chiappori, Charles C. Williams, Ben Creelan et al. · Journal of Clinical Oncology · 2018 · 47 citations

Medicine, Oncology, Pharmacology +17

Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression

Jason V. Evans, Shankar Suman, Mounika Goruganthu et al. · JNCI Journal of the National Cancer Institute · 2023 · 29 citations · Full text

Medicine, Oncology, Pharmacology +17